Holen Sie sich die Stockscreener-App
3.9334
0.34%
0.0134
Handel nachbörslich:
3.93
-0.0034
-0.09%
Schlusskurs vom Vortag:
$3.92
Offen:
$3.8721
24-Stunden-Volumen:
66,743
Relative Volume:
1.75
Marktkapitalisierung:
$68.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-5.5462
EPS:
-0.7092
Netto-Cashflow:
-
1W Leistung:
-6.35%
1M Leistung:
-8.10%
6M Leistung:
+25.27%
1J Leistung:
+120.98%
1-Tages-Spanne:
$3.87
$4.11
1-Wochen-Bereich:
$3.81
$4.6293
52-Wochen-Spanne:
$1.001
$5.87
Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile
Firmenname
Alterity Therapeutics Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ATHE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
3.9334 | 68.54M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Alterity Therapeutics Ltd Adr Stock (ATHE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-03 | Herabstufung | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | Eingeleitet | Maxim Group | Buy |
Alterity Therapeutics Ltd Adr Aktie (ATHE) Neueste Nachrichten
Alterity Therapeutics highlighted at MSA Congress - Investing.com
Alterity Therapeutics highlighted at MSA Congress By Investing.com - Investing.com India
Alterity Therapeutics reports Phase 2 data at MSA Congress - Investing.com
Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa
Alterity shares new phase 2 data on MSA treatment - Investing.com
Alterity shares new phase 2 data on MSA treatment By Investing.com - Investing.com India
Alterity Therapeutics announces regulatory notice - Investing.com
Alterity Therapeutics completes placement - Investing.com
Alterity Therapeutics announces regulatory notice By Investing.com - Investing.com UK
Alterity Therapeutics completes placement By Investing.com - Investing.com UK
ATHEAlterity Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
Alterity Concludes Open-Label Trial Patient Visits - Investing.com
Alterity Therapeutics announces compliance notice - Investing.com
Alterity Therapeutics Issues Over 1 Billion New Shares - TipRanks
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Alterity Therapeutics raises A$40M in placement - TipRanks
Alterity secures funding to advance MSA drug development - Investing.com India
JPMorgan Ceases Substantial Holding in Alterity Therapeutics - TipRanks
Alterity Therapeutics announces trading halt - Investing.com
Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement - TipRanks
JPMorgan Becomes Substantial Holder in Alterity Therapeutics - TipRanks
Alterity Therapeutics reports compliance with Takeovers Panel By Investing.com - Investing.com South Africa
Alterity Therapeutics reports compliance with Takeovers Panel - Investing.com
Alterity Therapeutics Discloses Equity Derivative Positions of Point72 - TipRanks
Alterity Therapeutics announces securities notice - Investing.com
Alterity Therapeutics Completes Significant Share Issuance - TipRanks
Alterity Therapeutics Quotes Over 164 Million Securities on ASX - TipRanks
Alterity Therapeutics announces ATH434 Phase 2 trial results - MSN
Alterity Therapeutics Announces Major Securities Placement - TipRanks
Alterity Therapeutics Secures Funding to Advance Neurodegenerative Drug Development - TipRanks
Alterity Therapeutics Reports Promising Phase 2 Results for MSA Drug ATH434 - TipRanks
Alterity Therapeutics Initiates Trading Halt Pending Phase II Trial Results - TipRanks
Predictive Oncology Inc (NASDAQ: POAI) Stock Is A Good Option To Consider - Stocks Register
Alterity Therapeutics reports quarterly activities - Investing.com
Alterity Therapeutics reports quarterly activities By Investing.com - Investing.com UK
Alterity Therapeutics Advances ATH434 Clinical Trials with Promising Data - TipRanks
Alterity Therapeutics Expands ASX Quoted Securities - TipRanks
Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025 - TipRanks
Alterity Therapeutics Highlights Key Milestones in Neurodegenerative Disease Pipeline - TipRanks
Opthea reports positive Phase 1b DME trial results - Investing.com
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead
symbol__ Stock Quote Price and Forecast - CNN
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
ASE Technology Holding Co., Ltd. American Depositary Shares (each representing (NY: ASX - Financial Content
A Full List of Australia ADRs - Investing.com Australia
Finanzdaten der Alterity Therapeutics Ltd Adr-Aktie (ATHE)
Es liegen keine Finanzdaten für Alterity Therapeutics Ltd Adr (ATHE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):